( June 12, 2026, 18:03 GMT | Official Statement) -- MLex Summary: Evidence obtained by Humana in antitrust litigation against Taro Pharmaceutical reflects "at most, ordinary parent-subsidiary oversight and executive supervision within a multinational enterprise," Taro told a Pennsylvania federal judge. "After exhaustive discovery, Humana cannot adduce proof that Taro Ltd. itself joined the alleged conspiracy or directed its indirect subsidiary, Taro USA, to do so," Taro said in a reply supporting its motion for summary judgment in the Eastern District of Pennsylvania.See attached document....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.